

JANUARY 2008

Ophthalmological Therapeutics:

Pipelines, Delivery Technologies, and Markets

by Hermann A.M. Mucke

***In-depth
report on this
dynamic market
poised for
growth***

The ophthalmology market, although a relatively small niche in the pharmaceutical industry, is more than worthwhile to track for multiple reasons:

- It is growing dynamically, and will likely continue this development unbroken for the next 2 or 3 decades.
- It offers scientific challenges that are definitely tough but not insurmountable, with the paths to success already discernible.

Continued on next page

Overview

- It is a market that analysts and investors can understand. Severe eye diseases are debilitating but not terminal conditions, and therefore most people know at least 1 person with severe vision impairment and can sympathize—which on the whole creates a more favorable basis for investments.

Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets provides a cutting-edge review of the challenges, achievements, and perspectives that characterize the inseparable therapeutic triad of ophthalmological pharmacology, surgery of the visual tract, and implantable ophthalmological medical devices. At annual sales of less than \$10 billion, this is a niche segment by the standards of the drug industry; however, it is a highly prestigious and profitable field. Because nothing that concerns intervention with the visual system is trivial, highly innovative specialist companies dominate development on the pharmacological as well as on the drug delivery side, which is immensely important in ophthalmological medicine.

Specifically, this report covers:

- A thorough therapeutic pipeline analysis
- Company profiles, including shifts in the corporate landscape since 2000
- A full discussion of eye disorders and potential treatments
- Current market dynamics
- Market predictions through 2015
- Expert commentary from leaders in the field

The market for prescription drugs to treat eye disorders will experience considerable and consistent growth throughout the next 10 years. The partial table below shows some of the research and development programs that are part of the growing field.

With its complexity and sensitivity—and with its tremendous importance to the quality of human life—the eye offers a broad range of challenges to pharmaceutical, surgical, and prosthetic science.

Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets discusses in detail all the aspects that make the ophthalmology market fascinating, promising, and profitable.

Table 3.2. Advanced Drug Candidates for Dry Eye Syndrome

Product Name and Developer	Active Principle	Stage
Rebamipide (Novartis)	2(1H)quinolone derivative	Phase III ongoing
Ecabet sodium (ISTA Pharmaceuticals)	12-Sulfodehydroabietic acid (natural phenantrene-type compound)	Phase IIb concluded
IDESTRIN (NP50301) (Nascent Pharmaceuticals)	17beta-estradiol ester	Phase IIb concluded
Prolacria (Inspire / Allergan / Santen)	Diquafosol (P2Y2 receptor agonist)	Phase III concluded
Vekacia (Novagali Pharmaceuticals)	Cyclosporin A	Phase III ongoing

Source: H.M. Pharma Consultancy

About the Author: Hermann A.M. Mucke, PhD, spent 17 years in academia and industry before he founded H.M. Pharma Consultancy (www.hmpharmacon.com) in 2000 to become an independent pharmaceutical consultant, analyst, and science author. His last industry position was Vice President R&D in a European pharmaceutical company, which he helped to take public on the Frankfurt Stock Exchange in 1999. Since then, Dr. Mucke, who holds a PhD in biochemistry from the University of Vienna (Austria), became a consultant and advisory board member for several European and American pharmaceutical companies and a regular reviewer of drugs and patents for Thomson Current Drugs and Ashley Publications. Dr. Mucke is based in Vienna.

Tables and Figures

Tables

Selected Artificial Tear Products Marketed in the United States and Europe
 Advanced Drug Candidates for Dry Eye Syndrome
 Antihistamines and Steroids for Topical Ocular Use in Allergic Conjunctivitis
 Newer Drugs for Intraocular Pressure Reduction Currently Used in the United States
 Sales and Revenue Figures for Visudyne and US Sales Share, 2000-2006
 Recent Patent Publications for Retinitis Pigmentosa
 Selected Alcon IP Documents Directed at Glaucoma and Published in 2006

Allergan Net Sales for Selected Prescription Ophthalmology Drugs, 2002-2006
 Bausch & Lomb Net Sales By Product Category, 2004-2006
 Fovea Pharmaceuticals' Ophthalmological Drug Pipeline
 The Current US Prescription Ophthalmological Drug Market and its Projected Development Through 2015-2020

Figures

A Cross-Sectional Schematic of the Human Eye
 Lens Transparency, Lens Aging, and Cataract Formation
 Fluid Formation and Outflow Through the Trabecular Meshwork
 Visual Acuity Changes in the US-European Phase III TAP Study Program for Visudyne

Table of Contents

Chapter 1: A Brief Introduction into Ophthalmology and its Markets

- 1.1. The Eye and Its Disorders
- 1.2. The Ophthalmology Market
- 1.3. High Unmet Medical Need and Scientific Challenges

Chapter 2: The Human Eye: A Unique Therapeutic Target

- 2.1. Anatomy of the Visual Apparatus
- 2.2. Characterizing and Quantifying Vision
- 2.3. Eye Surgery
Surgery for the Inner Eye
Surgical Correction of Opacification or Refractive Deviations
- 2.4. Ophthalmological Drug Delivery: Barriers and Strategies

Chapter 3: Disorders of the Anterior Eye: What You Can See is Not Always Easy to Treat

- 3.1. Dry Eye Syndrome
Existing Products for Dry Eye
Restasis
Advanced-Stage Investigational Drugs for Dry Eye
Early Experimental Therapeutic and Diagnostic Approaches to Dry Eye
- 3.2. Allergic Conjunctivitis
New Developments
- 3.3. Corneal Lesions and Dystrophy
- 3.4. Superficial Eye Infections
Infectious Conjunctivitis and Other
"Simple" Anterior Eye Infections
AzaSite: The First Ophthalmic Azithromycin
Antibiotic and Combination Products in Development
- 3.5. Tropical Eye Infections Make Inroads
Atypical Keratitis: A Growing Problem in Temperate Climate Zones
Trachoma: The World's Leading Cause of Preventable Blindness
River Blindness
- 3.6. Cataracts: Aging and Denaturation of the Lens
A Sector Dominated by Surgery
An Uphill Struggle for Drug Development
Pharmacoprevention for Posterior Capsular Opacification
Lens Regeneration and Tissue Biotechnology

- 3.7. Glaucoma: Pressure in the Front, Neurodegeneration in the Back of the Eye
Drugs for Intraocular Pressure Reduction
The Current Drug Landscape for Glaucoma
New Developments in the Glaucoma Drug Field

Chapter 4: Disorders of the Posterior Eye: At the Site of Vision

- 4.1. Vitrectomy: Radical Back-Eye Surgery for Multiple Causes
Vitreous Replacements
Preventing Formation of Cataracts as a Complication of Vitrectomy
Vitrase/Vitragan: A Potential Alternative to Vitrectomy for Hemorrhages
- 4.2. Diabetic Retinopathy and Retinal Vein Occlusion: A Lifestyle Disorder That Blinds
Laser Photocoagulation
Triamcinolone: Not Approved, but Widely Used, for DME
Ruxobistaurin: A Troubled Oral Drug Candidate for DME
More Experimental Drug Candidates for Retinopathy: The New and the Old
- 4.3. Age-Related Macular Degeneration: The Leading Cause of Blindness in the Industrialized World
Blood Vessel Sensitization to Phototherapy in Wet AMD
Visudyne: The Pioneer
Photrex and Optrin: 2 Follow-Up Photosensitizers
Biotechnology Anti-VEGF Products:
Rise of a Class
Macugen
Lucentis
Avastin: Off-Label Use in AMD and the Supply Restrictions Controversy
Follow-Up Developments in Ocular VEGF Control
Beyond VEGF: A Failure, and Many Hopes
Noninvasive Clinical Product Developments for AMD
Vigorous Preclinical and Patenting Activity Indicates More Approaches Under Way
- 4.4. Retinitis Pigmentosa: The Most Frequent Inherited Eye Disease
- 4.5. Intraocular Melanoma and Retinoblastoma: Posterior Eye Oncology

Choroidal Melanoma
Retinoblastoma

Chapter 5: Size, Structure, and Dynamics of the Ophthalmological Pharmaceutical Market

- 5.1. Small Innovators, Large Marketers
Alcon Laboratories
Allergan
Bausch & Lomb
Senju Pharmaceutical
Fovea Pharmaceuticals
ISTA Pharmaceuticals
MacuSight
Novagali Pharma
Ocularis Pharma
OSI Eyetech
OPKO Health
Othera Pharmaceuticals
Sirion Therapeutics
- 5.2. A Habitat for Specialized CROs
Iris Pharma and Clirophtha
PharmaNet Ophthalmology Group
Rx Development Resources
Global Clinical Trials Ophthalmology Research Services
- 5.3. Ophthalmic Market Dynamics and its Drivers
Demographics
Lifestyle
Capital Flows into the Ophthalmological Drug Development Market
- 5.4. Modeling the Ophthalmological Drug Market: Perspectives for 2015-2020

Chapter 6: Expert Interviews

- Cedric Francois, MD, PhD**, *President and CEO, Potentia Pharmaceuticals, Louisville, KY*
- Avner Ingerman, MD**, *Vice President and Ophthalmology Team Leader, Regeneron Pharmaceuticals, Tarrytown, NY*
- Samuel Reich**, *Executive Vice President of Ophthalmologics, OPKO Health, Miami, FL*
- Roger Vogel, MD**, *Cofounder and Chief Medical Officer, Sirion Therapeutics, Tampa, FL*

References

Company Index with Web Addresses

Related Report

Kinase Therapeutic Pipelines: An Assessment of Targets and Agents in Development

Recent developments reflect the explosion in the number of kinase inhibitors that have entered clinical development in the past few years:

- By the end of 2006, seven kinase inhibitors had reached the market, three in the period from December 2005-December 2006.
- Their collective sales exceeded \$4 billion.
- Three more kinase inhibitors have been approved in 2007.
- In addition to ongoing studies of approved kinase inhibitors seeking line extensions, a further 11 are in Phase III studies.
- More than 130 kinase inhibitors are reported to be in either Phase I or Phase II clinical development, with 47 reported to be in Phase II studies.

This report reviews the considerable array of drug development efforts directed at kinases and:

- Provides profiles of the activities of the major companies as well as the kinase inhibitors in development, and some of the specialist companies active in the field
- Assesses the potential impact of the more advanced kinase inhibitors, which offer significant market potential.
- Discusses some of the technical challenges faced in developing such inhibitors.
- Concludes with commentaries from leading experts in the field.

To view a table of contents and executive summary, please visit InsightPharmaReports.com

About Insight Pharma Reports

CHI Insight Pharma Reports are written by experts who collaborate with CHI to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Insight Pharma Reports are used by senior decision makers at life science companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Our regular clients include the top 50 pharmaceutical companies, top 100 biotechnology companies, and top 100 vendors of life science products and services. Typical purchasers are managers, directors, and VPs in business development, discovery research, clinical development, strategic planning, portfolio management, new product planning, and marketing.

Insight Pharma Reports offer:

- Current information and analysis of R&D technologies, therapeutic markets, and critical business issues.
- Analysis of the probability of success for various applications of each technology.
- Expert insight based on interviews with key personnel in companies at the forefront of technological advances. These experts share their views on their technology's current status, applications in drug development or diagnostics, future direction, and the general market environment.
- Competitive insight into the business strategies and activities of key companies.

Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets

Ophthalmological Therapeutics — January 2008 (est. 112 pages)

Pricing
 \$2,995.00

Single-Site/Operational Unit License*

\$3,750.00

Kinase Therapeutic Pipelines — December 2007 (164 pages)

\$2,995.00

\$3,750.00

Purchase both reports and receive a 10% discount

**Single-site licenses are multi-user, searchable, cut-and-paste ready PDFs*

Call for global license pricing; contact David Cunningham at 781-972-2472 or cunningham@healthtech.com

Total: \$ _____

Choose a payment option:

1. Enclosed is a check order payable to Cambridge Healthtech Institute, in U.S. currency. (In Massachusetts, add 5% sales tax.)

2. Purchase order number _____

3. Credit card: Amex Visa MC Diners Club #: _____ Exp. Date: _____ Sec. Code: _____

Cardholder: _____ Signature _____

Mr. Ms. Mrs. Dr. First Name: _____ Last Name: _____

Job Title: _____ Div./Dept. _____ Company _____

Address (please include Mail Stop, Room or Bldg. #): _____

City/State/Postal Code: _____ Country: _____

Telephone: _____ Fax: _____ E-Mail: _____

Please refer to the key code below

TO ORDER:

Web: InsightPharmaReports.com

Phone: 781-972-5444

Fax: 781-972-5425

E-mail: rlaraia@healthtech.com

Mail: Rose LaRaia
250 First Avenue, Suite 300
Needham, MA 02494